FDA approves US WorldMeds’ Lucemyra for opioid withdrawal symptoms
LOUISVILLE, Ky. — US WorldMeds announced that the U.S. Food and Drug Administration (FDA) approved Lucemyra (lofexidine) for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults. The FDA reviewed Lucemyra under Priority Review, which is granted to submissions for medications that would provide significant improvements in the safety or effectiveness of
